Spondyloarthritis & psoriatic arthritis
Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study
Authors' conclusion
Our study showed moderate and comparable construct validity for BASDAI- and ASDAS-based disease activity states, with the expected exception of association with CRP.
Study context
- Population
- Long-term BASDAI treat-to-target (T2T)-treated axial spondyloarthritis (axSpA) patients
- Participants
- 242 patients
- Exposure
- BASDAI vs ASDAS disease activity states
- Outcome
- Construct validity of BASDAI and ASDAS disease states
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Construct validity of disease states
| Group | Spearman's rho with fatigue | RR for increased C-reactive protein (CRP) (high disease activity) |
|---|---|---|
| BASDAI | 0.64 | 1.13 (95% CI 0.74-1.74) |
| ASDAS | 0.54 | 6.02 (95% CI 3.0-12.09) |
Spearman's rho with fatigue
BASDAI0.64
ASDAS0.54
RR for increased C-reactive protein (CRP) (high disease activity)
BASDAI1.13 (95% CI 0.74-1.74)
ASDAS6.02 (95% CI 3.0-12.09)
Observational data: associations, not effects.
Original publication
Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study. Scand J Rheumatol. Published 20 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →